Skip to content

Rhomboid Intercostal Plane Block vs Local Anesthetic Infilteration for Postoperative Analgesia After Thoracoscopic Surgery

Effects of Rhomboid Intercostal Plane Block for Postoperative Analgesia After Thoracoscopic Surgery Compared With Local Anesthetic Infilteration: A Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04821947
Enrollment
60
Registered
2021-03-30
Start date
2021-04-01
Completion date
2021-08-01
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

The purpose of the study is to evaluatethe effects of rhomboid intercostal block( RIB ) on postoperative pain after thoracoscopic surgery compared with local anesthetic infiltration ( LA )

Interventions

OTHERRhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine

for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula. After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ASA status I &II

Exclusion criteria

* Allergic constitution * Severe cardiovascular or hepatorenal insufficiency * Coagulation system disease * Injection site infection * Morbid obesity (BMI\>40 kg/m2).

Design outcomes

Primary

MeasureTime frameDescription
Total amount of postoperative analgesic consumptionFirst 24 hours postoperativetotal dose of postoperative tramadol and morphine
Visual Analogue Score ( VAS )First 24 hours postoperativeVAS will be measured at 1st, 2nd, 4th, 6th, 12th, 24th hours postoperative at rest and during cough

Contacts

Primary ContactHeba Fouad, MD
heba.toulan@gmail.com01221077317
Backup ContactRehab Abdelfattah, MD
rehab.fattah2002@gmail.com01110108610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026